Christian Rothermundt, Claudio Thurneisen, Richard Cathomas, Beat Müller, Walter Mingrone, Anita Hirschi-Blickenstorfer, Tobias Wehrhahn, Christian Ruf, Sacha I Rothschild, Bettina Seifert, Angelika Terbuch, Thomas Grassmugg, Regina Woelky, Christian Fankhauser, Thomas Kunit, Natalie F. Fischer, Natalie Fischer, Roman Inauen, Jörn Kamradt, Katrin Ziegler, Alan Haynes, Peter Jüni, Silke Gilessen

Publication Date: 29.08.2018
Swiss Med Wkly. 2018;148:w14674

Rothermundt C, et al. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Swiss Med Wkly. 2018;148:w14640. DOI:


Dr G Silke’s second affiliation has been added: a Klinik für Medizinische Onkologie und Hämatologie, Departement Innere Medizin, Kantonsspital St. Gallen, Switzerland


All references to “non-seminoma tumour(s)” are now “non-seminoma(s)”.

Summary: Results

The interquartile ranges for tumour size are reported separately for the two tumour types: 2.5‒5.0 and 2.3‒4.5 cm for seminomas and non-seminomas, respectively. The number of patients who did not receive therapy that conformed with guidelines was 11 (not 5).

Results: Tumour markers and stage of disease

In stage III seminoma, 72.7% of patients had marker-positive disease (not 66.7%).

Results: Table 4

For the patients with stage III seminoma, the percentages reported for each treatment regimen are the proportion of the prognosis group (not the treatment type).


Any tumour marker was elevated in non-seminoma stage I in 64.9% (not 64.5%) of patients.